7-OH, Kratom Extracts, and the Cost of Fear-Based Drug Narratives

Vero Beach Opioid Use Disorder, Kratom Extracts, and a Systems-Based Perspective

In recent months, public concern has grown around 7-hydroxymitragynine, often shortened to 7-OH, a potent alkaloid associated with some modern kratom-derived products.

In 2025, the FDA issued warning letters to companies marketing products containing 7-OH, describing them as potent opioid-receptor–active substances being sold in smoke shops, gas stations, and online marketplaces. That concern is not unfounded. From a pharmacological standpoint, 7-OH behaves very differently than traditional kratom leaf.

The World Health Organization has noted that both mitragynine and 7-OH act at the mu-opioid receptor, but that 7-OH has significantly greater binding affinity and intrinsic activity. In simpler terms, when products are engineered to concentrate 7-OH, they move closer to a narrow, opioid-like pharmacological profile.

At the same time, not all kratom products are the same.

Traditional kratom leaf typically contains very small amounts of 7-OH, often less than 1 percent. Some modern extract products, however, are reported to contain dramatically higher concentrations. This is not simply a stronger version of the same plant. It is a fundamentally different experience being delivered through a more concentrated and targeted mechanism.

This distinction matters.

Because while the risk is real, the way we talk about it matters just as much as the chemistry itself.

When Fear Replaces Education

In response to the rise of high-potency kratom extracts, some media narratives have begun using phrases like “gas station heroin.” That kind of language is powerful. It captures attention. It creates urgency. It also collapses important distinctions.

When whole-leaf kratom, mitragynine-dominant products, and highly concentrated 7-OH extracts are all grouped under a single emotionally charged label, the public becomes less informed, not more.

And there is another unintended consequence. Fear-based messaging does not reliably reduce substance use. In many cases, it does the opposite.

Research on health communication shows that when people feel manipulated, judged, or coerced by messaging, they often experience psychological reactance. Instead of changing behavior, they resist the message, distrust the source, or in some cases increase their interest in the very behavior being discouraged.

This is particularly relevant for populations already navigating:

• trauma
• dysregulation
• substance use patterns
• or mistrust of institutional systems

When the message becomes “this is dangerous, this is reckless, this is what bad people do,” many people do not feel educated. They feel alienated. And alienation is not a pathway to healing.

The Problem with the Criminal Justice Frame

There is a deeper pattern underneath this. When substance use is framed primarily through a criminal or moral lens, the system responds with punishment rather than understanding.

Stigma around substance use is associated with:

• delayed treatment seeking
• reduced access to care
• increased isolation
• poorer outcomes

When people feel judged or criminalized, they are less likely to reach out, less likely to be honest, and more likely to remain in cycles of secrecy and escalation.

What Happens When We Change the Frame

If fear-based messaging and criminalization do not reliably reduce harm, it raises a more important question:

What happens when we respond to substance use differently? Not with punishment or stigma, but with a system designed to understand and reduce harm.

This is where reflecting on Portugal becomes relevant, not as a perfect model, but as an example of how shifting policy can begin to reshape culture, perception, and ultimately, outcomes.

Portugal is often referenced in these conversations, but frequently in ways that are either oversimplified or misunderstood. Portugal did not legalize all drugs. Instead, in 2001, it decriminalized the possession and use of small amounts for personal use, while trafficking and distribution remained illegal. That distinction matters.

What changed was not the presence of substances, but the system’s response to people who use them. Instead of entering the criminal justice system, individuals were met with:

• clinical assessment
• treatment recommendations
• harm reduction strategies
• pathways toward reintegration

At the same time, Portugal invested in:

• treatment access
• public health infrastructure
• social support systems

The results were not immediate perfection, but they were meaningful. Research has shown:

• reductions in problematic substance use
• decreases in drug-related deaths
• significant declines in HIV transmission
• reduced burden on the criminal justice system

Portugal is now consistently ranked among the safer countries in the world, though it would be inaccurate to attribute that to drug policy alone. Safety reflects many variables. What can be said is this:

When the system shifted from punishment to care, outcomes improved. And that is the deeper relevance here. Because this is not just about policy. It is about orientation.

When we frame substance use as a criminal problem, we get criminal system responses.

When we frame it as a health and systems problem, we open the door to different outcomes.

The Rise of Extract Culture

What we are seeing with 7-OH is not just pharmacology. It reflects a broader cultural and industrial shift in how relief is produced, marketed, and consumed. A movement away from plant, relationship, and context, toward isolate, concentration, standardization, and consumption.

This is the industrialization of relief. And it is not new.

In the United States, particularly in the context of opioids, we have seen this pattern unfold repeatedly. When new molecules are developed or introduced, they are often framed as safer, more refined, and less prone to misuse than what came before. They are presented as advancements, improvements on older substances, solutions to existing problems.

OxyContin is one of the most well-known examples.

When it was introduced by Purdue Pharma in the 1990s, it was aggressively marketed to physicians as having a lower potential for abuse and dependence due to its extended-release formulation. Sales representatives were widely deployed into primary care offices and emergency departments, promoting the narrative that this was a safer, more controlled way to manage pain. These claims, presented as medically informed, were later shown to be deeply misleading and played a significant role in widespread overprescribing and the escalation of the opioid crisis in the United States.¹ ²

This pattern is not just historical, it is structural. It reveals how easily systems can be influenced when relief is framed as something that can be engineered, improved, and delivered more efficiently through chemistry alone.

A similar, though not identical, trajectory can be observed with kratom.

Kratom initially entered the Western market primarily as a plant-based substance, often consumed in powder or capsule form. In that form, it carries a broader alkaloid profile and generally lower potency compared to modern extract products, which may contribute to a different risk profile.³ But over time, the market began to shift. Companies started increasing potency through extracts, refining those extracts, and eventually isolating specific alkaloids such as 7-hydroxymitragynine. Each step moved further away from the original plant and closer to a highly targeted pharmacological effect.

With that shift came increasing potency, increasing predictability, and increasing potential for harm. Not simply because the substance became stronger, but because the relationship between the substance and the system using it fundamentally changed.

What was once a plant with variability and context became a standardized delivery system designed to produce a specific neurochemical outcome. This is the core of extract culture. It prioritizes efficiency over relationship, consistency over complexity, and outcome over process.

And while this can create the appearance of control, it often comes at the cost of integration. Because the more precisely relief is engineered and delivered, the less the system is required to participate in generating that relief.

Over time, this shifts regulation outward. And this is where the conversation moves beyond substances themselves. Because what we are seeing is not just a change in what people are using, but a change in how regulation is occurring within the system.

From a Functional Systems Regulation Theory perspective, this shift becomes even more important to understand.

Because the question is no longer simply what a substance does chemically.

The question becomes:

What role is this substance beginning to play within the system, and what capacity is it replacing, reinforcing, or reorganizing?

A Functional Systems Regulation Theory Lens

From a Functional Systems Regulation Theory perspective, the question is not simply what a substance does chemically, but what role it begins to play within a system organized around adaptation.

Central to this model is the concept of homeostatic patterning, the process through which biological and psychological systems calibrate to repeated conditions over time. The nervous system does not organize around what is optimal. It organizes around what is familiar, predictable, and repeatedly experienced.

In environments shaped by instability, chronic stress, or unresolved distress, systems often adapt toward patterns of heightened activation paired with inconsistent or externally mediated relief. Within this context, the drive is not toward avoidance of discomfort, but toward the restoration of a familiar regulatory state, even when that state is itself dysregulated.

The opioid system plays a central role in this process.

It is not merely a pathway for pleasure, but a core regulatory system involved in pain modulation, attachment, affective soothing, and the return from states of activation. Under typical conditions, this system is shaped through relational and environmental inputs, co-regulation, safety, rhythm, and connection.

However, when those conditions are absent, inconsistent, or insufficient, systems adapt.

Substances that provide rapid, predictable, and controllable relief can begin to function as external regulatory scaffolds, completing loops that the system has not been able to complete through endogenous or relational means.

Within this framework, the appeal of high-potency extracts is not adequately understood as hedonic seeking or simple avoidance. Rather, these substances may be experienced as functionally corrective, temporarily resolving dysregulated states by providing the relief the system has been conditioned to seek.

This is where homeostatic patterning becomes clinically relevant.

Repeated reliance on externalized forms of regulation reinforces the system’s orientation toward those pathways. Over time, this can lead to a narrowing of regulatory flexibility, with decreased reliance on internal capacity and diminished engagement with relational forms of regulation.

Importantly, this process is not best understood as a failure of will or character, but as an adaptive reorganization of the system in response to available conditions.

From this perspective, substance use is not the primary pathology.

It is an expression of a system attempting to regulate under constrained conditions.

This reframes the clinical task.

The goal is not simply to remove the substance, but to expand the system’s capacity for regulation, reintroduce relational and environmental scaffolding, and support the development of alternative pathways through which regulation can emerge.

As such, intervention must extend beyond symptom reduction and into systems-level reorganization.

Because without integration, even effective relief can reinforce the very patterns it temporarily resolves.

Or, stated more simply:

Dissolution reorganizes orientation. Integration determines whether that reorganization becomes coherence or rigidity.

"When regulation is consistently outsourced, the system adapts accordingly. The question is not whether it works, but what it is replacing."

If you or someone you care about is navigating substance use, there is a different way to approach this. You can reach out using the link below, send your name and phone number, and I will personally connect with you.

References